Commentary: Mapping out Novartis's "pathways" approach to R&D
27 August 2009
Asher Mullard
When Novartis announced plans to overhaul its lab space,
Scrip's senior science reporter Asher Mullard got to take a look at the company's R&D designs, business strategy and not-for-profit blueprints.
For several years now,
Novartis has been reorganising its drug discovery...
Please Login to read the full article.